Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | bromodomain adjacent to zinc finger domain, 2B | Starlite/ChEMBL | No references |
Homo sapiens | glutaminase | Starlite/ChEMBL | No references |
Giardia intestinalis | Putative fructose-1,6-bisphosphate aldolase | Starlite/ChEMBL | No references |
Homo sapiens | microtubule-associated protein tau | Starlite/ChEMBL | No references |
Homo sapiens | glucosidase, alpha | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Candida albicans | fructose-bisphosphate aldolase | Putative fructose-1,6-bisphosphate aldolase | 323 aa | 358 aa | 22.6 % |
Mycobacterium leprae | Probable fructose bisphosphate aldolase Fba | Putative fructose-1,6-bisphosphate aldolase | 323 aa | 361 aa | 25.8 % |
Mycobacterium tuberculosis | Probable fructose-bisphosphate aldolase Fba | Putative fructose-1,6-bisphosphate aldolase | 323 aa | 361 aa | 25.5 % |
Candida albicans | fructose-bisphosphate aldolase | Putative fructose-1,6-bisphosphate aldolase | 323 aa | 358 aa | 22.6 % |
Mycobacterium ulcerans | fructose-bisphosphate aldolase | Putative fructose-1,6-bisphosphate aldolase | 323 aa | 361 aa | 26.9 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | vesicular acetylcholine transporter unc-17 | 0.2117 | 0.671 | 0.6696 |
Schistosoma mansoni | glutaminase | 0.033 | 0.0965 | 0.1382 |
Loa Loa (eye worm) | glutaminase | 0.033 | 0.0965 | 0.0925 |
Brugia malayi | glutaminase DH11.1 | 0.033 | 0.0965 | 0.0965 |
Entamoeba histolytica | fructose-1,6-bisphosphate aldolase, putative | 0.0353 | 0.1038 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0085 | 0.0178 | 0.0135 |
Echinococcus multilocularis | vesicular acetylcholine transporter | 0.2117 | 0.671 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.0069 | 0.0025 |
Schistosoma mansoni | microtubule-associated protein tau | 0.0833 | 0.2583 | 0.381 |
Brugia malayi | vesicular acetylcholine transporter unc-17 | 0.2117 | 0.671 | 0.671 |
Trypanosoma brucei | C-8 sterol isomerase, putative | 0.3139 | 1 | 1 |
Brugia malayi | Glycosyl hydrolases family 31 protein | 0.0044 | 0.0044 | 0.0044 |
Leishmania major | C-8 sterol isomerase-like protein | 0.3139 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0046 | 0.0052 | 0.0009 |
Mycobacterium ulcerans | glutaminase | 0.033 | 0.0965 | 1 |
Toxoplasma gondii | glycosyl hydrolase, family 31 protein | 0.0044 | 0.0044 | 0.5 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 0.1038 | 1 |
Echinococcus granulosus | neutral alpha glucosidase AB | 0.0044 | 0.0044 | 0.0001 |
Echinococcus multilocularis | lysosomal alpha glucosidase | 0.0197 | 0.0536 | 0.074 |
Echinococcus multilocularis | neutral alpha glucosidase AB | 0.0044 | 0.0044 | 0.0001 |
Loa Loa (eye worm) | hypothetical protein | 0.1605 | 0.5064 | 0.5042 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 0.1038 | 1 |
Brugia malayi | Glycosyl hydrolases family 31 protein | 0.0197 | 0.0536 | 0.0536 |
Echinococcus multilocularis | lysosomal alpha glucosidase | 0.0197 | 0.0536 | 0.074 |
Brugia malayi | Bromodomain containing protein | 0.0091 | 0.0195 | 0.0195 |
Treponema pallidum | fructose-bisphosphate aldolase | 0.0353 | 0.1038 | 0.5 |
Mycobacterium tuberculosis | Probable fructose-bisphosphate aldolase Fba | 0.0172 | 0.0458 | 0.5 |
Entamoeba histolytica | fructose-1,6-bisphosphate aldolase, putative | 0.0353 | 0.1038 | 1 |
Echinococcus granulosus | microtubule associated protein 2 | 0.0833 | 0.2583 | 0.381 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0072 | 0.0135 | 0.0138 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0072 | 0.0135 | 0.0138 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 0.1038 | 1 |
Trichomonas vaginalis | glutaminase, putative | 0.033 | 0.0965 | 0.9262 |
Mycobacterium leprae | Probable fructose bisphosphate aldolase Fba | 0.0172 | 0.0458 | 0.5 |
Schistosoma mansoni | vesicular acetylcholine transporter | 0.2117 | 0.671 | 1 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 0.1038 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.3139 | 1 | 1 |
Schistosoma mansoni | alpha-glucosidase | 0.0169 | 0.0448 | 0.0606 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 0.1038 | 1 |
Schistosoma mansoni | bromodomain containing protein | 0.0076 | 0.0149 | 0.0158 |
Schistosoma mansoni | alpha-glucosidase | 0.0169 | 0.0448 | 0.0606 |
Onchocerca volvulus | Vesicular acetylcholine transporter homolog | 0.2117 | 0.671 | 1 |
Loa Loa (eye worm) | glycosyl hydrolase family 31 protein | 0.0197 | 0.0536 | 0.0494 |
Echinococcus multilocularis | microtubule associated protein 2 | 0.0833 | 0.2583 | 0.381 |
Loa Loa (eye worm) | hypothetical protein | 0.0049 | 0.0061 | 0.0018 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 0.1038 | 1 |
Giardia lamblia | Fructose-bisphosphate aldolase | 0.0353 | 0.1038 | 0.5 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 0.1038 | 1 |
Echinococcus granulosus | vesicular acetylcholine transporter | 0.2117 | 0.671 | 1 |
Loa Loa (eye worm) | glutaminase 2 | 0.033 | 0.0965 | 0.0925 |
Echinococcus granulosus | lysosomal alpha glucosidase | 0.0197 | 0.0536 | 0.074 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 0.1038 | 1 |
Brugia malayi | Bromodomain containing protein | 0.0046 | 0.0052 | 0.0052 |
Trypanosoma cruzi | C-8 sterol isomerase, putative | 0.3139 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.7079 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Potency (functional) | 0.9285 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 5 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia. (Class of assay: confirmatory) [Related pubchem assays: 2472, 2464 ] | ChEMBL. | No reference |
Potency (functional) | = 7.0795 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen. (Class of assay: confirmatory) [Related pubchem assays: 1473, 1466 ] | ChEMBL. | No reference |
Potency (functional) | 7.9433 uM | PubChem BioAssay. qHTS for Inhibitors of Glutaminase (GLS). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | = 15.8489 um | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Potency (functional) | 26.8545 uM | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | ChEMBL. | No reference |
Potency (functional) | 29.081 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.